Table 1.
Multivariate logistic regression of factors associated with severe liver disease
| Multivariate analysis | |||||
|---|---|---|---|---|---|
| Factors |
Patients (n = 4 343) |
% SLD |
% missing data |
Complete Case (n = 2 130) aOR* (95% CI*) |
Multiple Imputation (n = 4 343) aOR* (95% CI*) M = 30 imputed datasets |
| Period of inclusion |
|
|
|
|
|
| 2001-2003 |
2330 |
7.0 |
|
|
|
| 2004-2007 |
2013 |
9.5 |
|
|
|
| Sex |
|
|
|
|
|
| Female |
993 |
4.2 |
|
1.0 |
1.0 |
| Male |
3350 |
9.3 |
|
1.8 [1.1,3.0] |
2.0 [1.4,2.9] |
| Age |
|
|
|
|
|
| ≤ 40 years |
2435 |
3.9 |
|
1.0 |
1.0 |
| > 40 years |
1908 |
13.6 |
|
2.2 [1.5,3.3] |
2.3 [1.7,3.1] |
| Time between 1st HCV + test and referral |
|
|
|
|
|
| < 1 year |
1728 |
6.7 |
|
|
|
| ≥ 1 year |
2163 |
8.7 |
|
|
|
| Missing |
452 |
11.5 |
10.4 |
|
|
| Duration of HCV infection at referral† |
|
|
|
|
|
| < 18 years |
1709 |
3.0 |
|
1.0 |
1.0 |
| ≥ 18 years |
2002 |
12.5 |
|
3.1 [2.0,5.1] |
2.6 [1.8,3.7] |
| Missing |
632 |
8.2 |
14.6 |
|
|
| History of excessive alcohol intake‡ |
|
|
|
|
|
| No |
2015 |
4.5 |
|
1.0 |
1.0 |
| Yes |
1847 |
13.2 |
|
2.6 [1.8,3.7] |
2.8 [2.2,3.7] |
| Missing |
481 |
4.4 |
11.1 |
|
|
| HbsAg status |
|
|
|
|
|
| Negative |
3570 |
8.3 |
|
1.0 |
|
| Positive |
89 |
13.5 |
|
2.4 [1.0,5.9] |
|
| Missing |
684 |
6.7 |
15.7 |
|
|
| HIV serostatus |
|
|
|
|
|
| Negative |
3342 |
8.2 |
|
|
1.0 |
| Positive |
294 |
14.0 |
|
|
1.8 [1.2,2.6] |
| Missing |
707 |
5.7 |
16.3 |
|
|
| HCV genotype 3 |
|
|
|
|
|
| No |
2083 |
7.2 |
|
1.0 |
1.0 |
| Yes |
1117 |
10.3 |
|
1.5 [1.1,2.0] |
1.6 [1.3,2.1] |
| Missing | 1143 | 7.8 | 26.3 | ||
*aOR, adjusted Odds Ratio; CI, confidence interval; SLD, severe liver disease (cirrhosis, hepatocellular carcinoma); HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus.
† Time from suspected year of infection to year of referral to the reference centre. Suspected year of HCV infection is defined as year of the last HCV negative test performed during the drug-use period or year of first drug injection.
‡ >210 g/week for women and >280 g/week for men.
Complete case and multiple imputation analyses were applied to a population of HCV-RNA positive drug users newly referred in hepatology reference centres in France, 2001–2007.